Последна проверка на аптечни данни:

ATC е класификация по активно вещество и терапевтична група. Общ код не означава, че продуктите са взаимозаменяеми. Сверете формата и концентрацията на конкретния вариант.

J07B

VIRAL VACCINES

Кодът J07B е на трето ниво от анатомо-терапевтично-химичната (ATC) класификация на СЗО: фармакологична подгрупа. В регистрите на ИАЛ и EMA към групата и подгрупите ѝ са отнесени 64 лекарствени записа с 62 търговски имена от 19 притежатели на разрешение за употреба. Записите са в 25 ATC кода на петото ниво (химично вещество); най-много имат influenza, inactivated, split virus or surface antigen (18), hepatitis B, purified antigen (4), hepatitis A, inactivated, whole virus (4). По данните от регистрите 63 се отпускат по лекарско предписание; за 1 режимът на отпускане не е посочен в справочните данни. 22 са с национално разрешение (ИАЛ), 42 – с централизирано разрешение в ЕС (EMA). Листовката на 43 от тях е на сайта; раздел със съмнение за грешка при разчитането на скана е скрит и се чете в официалния документ. За останалите е посочен официалният документ, когато регистърът го публикува.

Източници: регистрите на ИАЛ и EMA, Позитивният лекарствен списък на НЗОК; обхват и дата на данните.

Наименование на групата: WHO Collaborating Centre for Drug Statistics Methodology

Подгрупи

ATC класификацията е дърво. Тази категория се разделя на 11 подгрупи.

Лекарствени продукти в тази категория

64 продукта в тази категория и подгрупите ѝ.

Търговско име Концентрация
Abrysvo --¹ After reconstitution, one dose (0.5 mL) contains: RSV subgroup A stabilised prefusion F antigen*,** 60 micrograms RSV subgroup B stabilised prefusion F antigen*,** 60 micrograms * glycoprotein F stabilised in the prefusion conformation ** produced in Chinese Hamster Ovary cells by recombinant DNA technology
Adjupanrix --¹ After mixing, 1 dose (0.5 ml) contains: Split influenza virus, inactivated, containing antigen* equivalent to: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14) 3.75 μg** * propagated in eggs ** haemagglutinin AS03 adjuvant composed of squalene (10.69 mg), DL-alfa-tocopherol (11.86 mg) and polysorbate 80 (4.86 mg)
Aflunov --¹ Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: A/turkey/Turkey/1/2005 (H5N1) - like strain (NIBRG-23) (clade 2.2.1) 7.5 micrograms** per 0.5 ml dose * propagated in fertilised hens’ eggs from healthy chicken flocks ** expressed in microgram haemagglutinin Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams
Ambirix --¹ 1 dose (1 ml) contains: Hepatitis A virus (inactivated)¹,² 720 ELISA Units Hepatitis B surface antigen³,⁴ 20 micrograms ¹Produced on human diploid (MRC-5) cells ²Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al³+ ³Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology ⁴Adsorbed on aluminium phosphate 0.4 milligrams Al³+
Anti - CHF Vaccine —
AREXVY --¹ After reconstitution, one dose (0.5 mL) contains: RSVPreF3¹ antigen²,³ 120 micrograms ¹ Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation = RSVPreF3 ² RSVPreF3 produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology ³ adjuvanted with AS01E containing: plant extract Quillaja saponaria Molina, fraction 21 (QS-21) 25 micrograms 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota 25 micrograms
Aujemflu --¹ Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains*: <A/H1N1 strain> 45 micrograms HA** <A/H3N2 strain> 45 micrograms HA** <B Victoria strain> 45 micrograms HA** per 1.0 ml dose ………………………………………. * propagated in Madin Darby Canine Kidney (MDCK) cells ** haemagglutinin Adjuvant MF59C.1 containing per 1.0 ml dose: squalene 19.5 milligrams polysorbate 80 2.35 milligrams sorbitan trioleate 2.35 milligrams sodium citrate 1.32 milligrams citric acid 0.08 milligrams
Avaxim 160U adult 0,5 ml
Avaxim 80U Pediatric 0,5 ml
BIMERVAX --¹ One dose (0.5 mL) contains: 40 micrograms of selvacovatein adjuvanted with SQBA (EU/1/22/1709/001-004). Selvacovatein is a SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351 and B.1.1.7 strains) produced by recombinant DNA technology using a plasmid expression vector in a CHO cell line. SQBA adjuvant containing per 0.5 mL dose: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) and water for injections.
Celldemic --¹ One dose (0.5 ml) contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of strain*: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) 7.5 micrograms** * propagated in Madin Darby Canine Kidney (MDCK) cells ** expressed in micrograms haemagglutinin. Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams
Cervarix --¹ 1 dose (0.5 ml) contains: Human Papillomavirus1 type 16 L1 protein²,³,⁴ 20 micrograms Human Papillomavirus1 type 18 L1 protein²,³,⁴ 20 micrograms 1Human Papillomavirus = HPV ²adjuvanted by AS04 containing: 3-O-desacyl-4’- monophosphoryl lipid A (MPL)³ 50 micrograms ³ adsorbed on aluminium hydroxide, hydrated (Al(OH)₃) 0.5 milligrams Al³+ in total ⁴L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from Trichoplusia ni.
COMIRNATY -¹⁵ COMIRNATY JN.1 30 micrograms/dose dispersion for injection (EU/1/20/1528/028-031, EU/1/20/1528/043): 1 dose (0.3 mL) contains 30 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles). Bretovameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).
Efluelda —
Efluelda Tetra —
Engerix В 0,5 ml
Engerix В 1 ml
Ervebo --¹ One dose (1 mL) contains: Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP¹² live, attenuated) ≥72 million pfu³ ¹Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP) ²Produced in Vero cells ³pfu= plaque-forming units
Fendrix --¹ 1 dose (0.5 ml) contains: Hepatitis B surface antigen¹,²,³ 20 micrograms ¹adjuvanted by AS04C containing: - 3-O-desacyl-4’- monophosphoryl lipid A (MPL)² 50 micrograms ²adsorbed on aluminium phosphate (0.5 milligrams Al³+ in total) ³produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
Fluad --¹ Each 0.5 ml dose contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains*: A/Missouri/11/2025 (H1N1)pdm09-like strain (A/Missouri/11/2025, IVR-279) 15 micrograms HA** A/Darwin/1454/2025 (H3N2)-like strain (A/Michigan/105/2025, IVR-285) 15 micrograms HA** B/Tokyo/EIS13-175/2025-like strain (B/Tokyo/EIS13-175/2025, wild type) 15 micrograms HA** *propagated in fertilised hens’ eggs from healthy chicken flocks and adjuvanted with MF59C.1 **haemagglutinin
Fluarix —
Fluarix Tetra —
Flucelvax --¹ Each 0.5 ml dose contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains*: A/Missouri/11/2025 (H1N1)pdm09-like strain (A/Tasmania/318/2025, CVR-351) 15 micrograms HA** A/Darwin/1415/2025 (H3N2)-like strain (A/Tasmania/787/2025, CVR-388) 15 micrograms HA** B/Pennsylvania/14/2025-like strain (B/Arizona/21/2025, wild type) 15 micrograms HA** * propagated in Madin Darby Canine Kidney (MDCK) cells ** haemagglutinin
Fluenz --¹ 1 dose (0.2 ml) contains: Reassortant influenza virus* (live attenuated) of the following three strains**: A/Missouri/11/2025 (H1N1) pdm09-like strain (A/Switzerland/6849/2025, MEDI 400592) 10⁷.⁰±⁰.⁵ FFU*** A/Darwin/1454/2025 (H3N2)-like strain (A/Darwin/1369/2025, MEDI 406666) 10⁷.⁰±⁰.⁵ FFU*** B/Tokyo/EIS13-175/2025-like strain (B/Perth/115/2025, MEDI 407730) 10⁷.⁰±⁰.⁵ FFU*** * Propagated in fertilised hens’ eggs from healthy chicken flocks. ** Produced in VERO cells by reverse genetic technology. This product contains genetically modified organisms (GMOs). *** Fluorescent Focus Units.
Foclivia 15 µg/ml
Gardasil --¹ 1 dose (0.5 ml) contains approximately: Human Papillomavirus¹ Type 6 L1 protein², ³ 20 µg Human Papillomavirus¹ Type 11 L1 protein², ³ 40 µg Human Papillomavirus¹ Type 16 L1 protein², ³ 40 µg Human Papillomavirus¹ Type 18 L1 protein², ³ 20 µg ¹ Human Papillomavirus = HPV ² L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology ³ adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al)
Gardasil 9 --¹ 1 dose (0.5 ml) contains approximately: Human Papillomavirus¹ Type 6 L1 protein²,³ 30 micrograms Human Papillomavirus¹ Type 11 L1 protein²,³ 40 micrograms Human Papillomavirus¹ Type 16 L1 protein²,³ 60 micrograms Human Papillomavirus¹ Type 18 L1 protein²,³ 40 micrograms Human Papillomavirus¹ Type 31 L1 protein²,³ 20 micrograms Human Papillomavirus¹ Type 33 L1 protein²,³ 20 micrograms Human Papillomavirus¹ Type 45 L1 protein²,³ 20 micrograms Human Papillomavirus¹ Type 52 L1 protein²,³ 20 micrograms Human Papillomavirus¹ Type 58 L1 protein²,³ 20 micrograms ¹ Human Papillomavirus = HPV ² L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology ³ adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.5 milligrams Al)
Havrix 1440 —
Havrix 720 —
HBVAXPRO 5 µg/0.5 ml
HEPLISAV B --¹ One dose (0.5 mL) contains: Hepatitis B surface antigen¹,² 20 µg ¹Adjuvanted with 3000 micrograms 1018 adjuvant, a 22-mer immunostimulatory sequence oligonucleotide ²Produced in Hansenula polymorpha yeast cells by recombinant DNA technology
IMVANEX --¹ Virus titer no less than of 5 x 10⁷ Inf.U One dose (0.5 ml) contains: Modified Vaccinia Ankara – Bavarian Nordic Live virus no less than 5 x 10⁷ Inf.U * *infectious units Produced in chick embryo cells
Incellipan --¹ One dose (0.5 ml) contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of strain*: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) 7.5 micrograms** * propagated in Madin Darby Canine Kidney (MDCK) cells ** expressed in micrograms haemagglutinin. Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams
Influvac —
Influvac Tetra —
IXCHIQ --¹ After reconstitution, one dose (0.5 ml) contains: Chikungunya virus (CHIKV) Δ5nsP3 strain (live, attenuated)* not less than 3.0 log₁₀ TCID₅₀** *Produced in Vero cells ** 50% tissue culture infectious dose
Ixiaro --¹ 1 dose (0.5 ml) contains: Japanese encephalitis virus strain SA₁₄-14-2 (inactivated)¹-² 6 AU³ corresponding to a potency of ≤ 460 ng ED₅₀ ¹ produced in Vero cells ² adsorbed on aluminium hydroxide, hydrated (approximately 0.25 milligrams Al³+) ³ Antigen Units
Kostaive --¹ After reconstitution with 10 mL of sterile 0.9% Sodium Chloride Injection, one dose (0.5 mL) contains 5 micrograms of Zapomeran, a COVID-19 mRNA (encapsulated in lipid nanoparticles). Zapomeran is a single-stranded, 5'-capped messenger RNA (mRNA) replicon (self-amplifying mRNA), produced using a cell-free in vitro transcription from the corresponding DNA templates encoding a replicase and the spike glycoprotein of the G clade D614G variant of SARS-CoV-2.
mCOMBRIAX --¹ One dose (0.32 mL) contains 31.7 micrograms of total RNA. mCOMBRIAX is single stranded, 5’-capped messenger RNAs (mRNAs) produced using a cell-free in vitro transcription from the corresponding DNA template, encoding seasonal influenza haemagglutinin (HA) glycoproteins: A/H1N1, A/H3N2, B/Victoria, and the linked N terminal domain and receptor-binding domain of the viral spike (S) protein of SARS CoV 2. Influenza virus strains and SARS CoV 2 composition per 0.32 mL dose: A/Wisconsin/67/2022 (A/H1N1 pdm09) .................…………………............8.3 micrograms RNA A/Darwin/6/2021 (A/H3N2) ..................................………………..............8.3 micrograms RNA B/Austria/1359417/2021 (B/Victoria lineage) ......................................8.3 micrograms RNA SARS CoV 2 Omicron XBB.1.5 ...........................................................6.7 micrograms RNA
M-M-RvaxPro --¹ After reconstitution, one dose (0.5 ml) contains: Measles virus**¹ Enders' Edmonston strain (live, attenuated) not less than 1x10³ CCID50* Mumps virus**¹ Jeryl Lynn™ [Level B] strain (live, attenuated) not less than 12.5x10³ CCID50* Rubella virus**² Wistar RA 27/3 strain (live, attenuated) not less than 1x10³ CCID50* *50% tissue culture infectious dose **¹ Produced in chick embryo cells. **² Produced in WI-38 human diploid lung fibroblasts.
mNEXSPIKE --¹ One dose (0.2 mL) contains 10 micrograms of SARS-CoV-2 mRNA. mNEXSPIKE is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA template, encoding the N-terminal domain and receptor-binding domain of the viral spike (S) protein of SARS-CoV-2 (XBB.1.5).
mRESVIA --¹ One dose (0.5 mL) contains 50 micrograms of RSV mRNA (nucleoside modified) encapsulated in lipid nanoparticles.
Nuvaxovid --¹ One dose (0.5 ml) contains 5 µg of the of SARS-CoV-2 spike protein* and is adjuvanted with Matrix-M. Adjuvant Matrix-M containing per 0.5 mL dose: Fraction-A (42.5 µg) and Fraction-C (7.5 µg) of Quillaja saponaria Molina extract. * produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera frugiperda species.
Pandemic influenza vaccine H5N1 AstraZeneca --¹ 1 dose (0.2 ml) contains: Reassortant influenza virus* (live attenuated) of the following strain***: A/Vietnam/1203/2004 (H5N1) strain (A/Vietnam/1203/2004, MEDI 0141000136) 10⁷.⁰±⁰.⁵ FFU** * propagated in fertilised hens’ eggs from healthy chicken flocks. ** produced in VERO cells by reverse genetic technology. This product contains a genetically modified organism (GMO). *** fluorescent focus units
Priorix —
Priorix-Tetra —
ProQuad --¹ After reconstitution, one dose (0.5 ml) contains: Measles virus¹ Enders’ Edmonston strain (live, attenuated) not less than 3.00 log10 CCID50* Mumps virus¹ Jeryl Lynn™ (Level B) strain (live, attenuated) not less than 4.30 log10 CCID50* Rubella virus² Wistar RA 27/3 strain (live, attenuated) not less than 3.00 log10 CCID50* Varicella virus³ Oka/Merck strain (live, attenuated) not less than 3.99 log10 PFU** *50% cell culture infectious dose **plaque-forming units ¹ Produced in chick embryo cells. ² Produced in human diploid lung (WI-38) fibroblasts. ³ Produced in human diploid (MRC-5) cells.
Qdenga --¹ After reconstitution, 1 dose (0.5 mL) contains: Dengue virus serotype 1 (live, attenuated)*: ≥ 3.3 log10 PFU**/dose Dengue virus serotype 2 (live, attenuated)#: ≥ 2.7 log10 PFU**/dose Dengue virus serotype 3 (live, attenuated)*: ≥ 4.0 log10 PFU**/dose Dengue virus serotype 4 (live, attenuated)*: ≥ 4.5 log10 PFU**/dose *Produced in Vero cells by recombinant DNA technology. Genes of serotype-specific surface proteins engineered into dengue type 2 backbone #Produced in Vero cells by recombinant DNA technology **PFU = Plaque-forming units
Rabipur —
Rabipur —
Rotarix --¹ not less than 10⁶·⁰ CCID₅₀
RotaTeq --¹ One dose (2 ml) contains: Rotavirus type* G1 not less than 2.2 x 10⁶ IU¹, ² Rotavirus type* G2 not less than 2.8 x 10⁶ IU¹, ² Rotavirus type* G3 not less than 2.2 x 10⁶ IU¹, ² Rotavirus type* G4 not less than 2.0 x 10⁶ IU¹, ² Rotavirus type* P1A[8] not less than 2.3 x 10⁶ IU¹, ² * Human-bovine rotavirus reassortants (live), produced in Vero cells. ¹ Infectious Units ² As lower confidence limit (p = 0.95)
Shingrix --¹ After reconstitution, one dose (0.5 mL) contains: Varicella Zoster Virus¹ glycoprotein E antigen²,³ 50 micrograms ¹ Varicella Zoster Virus = VZV ² adjuvanted with AS01B containing: plant extract Quillaja saponaria Molina, fraction 21 (QS-21) 50 micrograms 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota 50 micrograms ³ glycoprotein E (gE) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology
Spikevax --⁶ One dose (0.5 mL) contains 50 micrograms of SARS-CoV-2 JN.1 mRNA, a COVID-19 mRNA Vaccine (nucleoside modified) (embedded in lipid nanoparticles). One dose (0.25 mL) contains 25 micrograms of SARS-CoV-2 JN.1 mRNA, a COVID-19 mRNA Vaccine (nucleoside modified) (embedded in lipid nanoparticles). SARS-CoV-2 JN.1 mRNA is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (JN.1).
Stamaril —
Supemtek --¹ One dose (0.5 ml) contains: Influenza virus haemagglutinin (HA) proteins, of the following strains*: A/California/07/2009 (H1N1)pdm09-like strain (A/California/07/2009) 45 micrograms HA A/Texas/50/2012 (H3N2)-like strain (A/Texas/50/2012) 45 micrograms HA B/Brisbane/60/2008-like strain (B/Brisbane/60/2008) 45 micrograms HA * produced by recombinant DNA technology using a baculovirus expression system in a continuous insect cell line that is derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda.
Supemtek Tetra --¹ One dose (0.5 mL) contains: Influenza virus haemagglutinin (HA) proteins, of the following strains*: A/XXXXXX (H1N1).................................. 45 micrograms HA A/XXXXXX (H3N2).................................. 45 micrograms HA B/XXXXXX............................................... 45 micrograms HA B/XXXXXX............................................... 45 micrograms HA * produced by recombinant DNA technology using a baculovirus expression system in a continuous insect cell line that is derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda.
Twinrix Adult 1 dose (1 ml) contains: Hepatitis A virus (inactivated)¹,² 720 ELISA Units Hepatitis B surface antigen³,4 20 micrograms ¹Produced on human diploid (MRC-5) cells ²Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al³+ ³Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate 0.4 milligrams Al³+
Twinrix Paediatric --¹ 1 dose (0.5 ml): Hepatitis A virus (inactivated)¹,² 360 ELISA Units Hepatitis B surface antigen³,⁴ 10 micrograms ¹Produced on human diploid (MRC-5) cells ²Adsorbed on aluminium hydroxide, hydrated 0.025 milligrams Al³+ ³Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology ⁴Adsorbed on aluminium phosphate 0.2 milligrams Al³+
Varivax —
Vaxigrip —
Vaxigrip Tetra —
Verorab —
Zoonotic Influenza Vaccine Seqirus --¹ Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain: A/Astrakhan/3212/2020 (H5N8) - like strain (CBER-RG8A) (clade 2.3.4.4b) 7.5 micrograms** per 0.5 ml dose * propagated in fertilised hens’ eggs from healthy chicken flocks ** expressed in microgram haemagglutinin Adjuvant MF59C.1 containing: squalene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams sodium citrate 0.66 milligrams citric acid 0.04 milligrams